David A Proia

Summary

Publications

  1. pmc Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 6:e18552. 2011
  2. doi request reprint Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib
    Jaime Acquaviva
    Corresponding Author David A Proia, Synta Pharmaceuticals Corp, 125 Hartwell Avenue, Lexington, MA 02421
    Mol Cancer Ther 13:353-63. 2014
  3. pmc Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
  4. doi request reprint Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
    Jim Sang
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Cancer Discov 3:430-43. 2013
  5. doi request reprint Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
  6. pmc Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
  7. doi request reprint Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012
  8. doi request reprint Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
    Julie C Friedland
    Synta Pharmaceuticals Corp, 125 Hartwell Avenue, Lexington, MA, 02421, USA
    Invest New Drugs 32:14-24. 2014
  9. pmc Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
    Ronald K Blackman
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e29798. 2012
  10. doi request reprint Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise
    David A Proia
    Authors Affiliation Synta Pharmaceuticals Corp, Lexington, Massachusetts
    Cancer Res 74:1294-300. 2014

Collaborators

  • Richard C Bates
  • Yuan Liu
  • D Ross Camidge
  • Robert C Doebele
  • Christine M Lovly
  • Alice T Shaw
  • Guri Giaever
  • Jaime Acquaviva
  • Jim Sang
  • Suqin He
  • Julie C Friedland
  • Donald L Smith
  • Chaohua Zhang
  • Manuel Sequeira
  • Yumiko Wada
  • Ronald K Blackman
  • John Paul Jimenez
  • Weiwen Ying
  • Ayesha A Shafi
  • Iman El-Hariry
  • Stephan W Morris
  • Qin Jiang
  • Nancy L Weigel
  • Liquan Xue
  • Dan Zhou
  • James Barsoum
  • Jamie Acquaviva
  • Corey Nislow
  • Philippe Marchetti
  • Kahlin Cheung-Ong
  • Keizo Koya
  • Zhenjian Du
  • Takayo Inoue
  • Jane Kepros
  • Patricia E Rao
  • Aurélie Jonneaux
  • Shuxia Ye
  • Luisa Shin Ogawa
  • Lijun Sun
  • Noriaki Tatsuta
  • Jerome Kluza
  • Marinella Gebbia
  • Kevin P Foley

Detail Information

Publications10

  1. pmc Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 6:e18552. 2011
    ..Overall, our findings support Hsp90 inhibition as a novel therapeutic approach for combating diseases dependent on JAK/STAT signaling, with the multimodal action of ganetespib demonstrating advantages over JAK-specific inhibitors...
  2. doi request reprint Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib
    Jaime Acquaviva
    Corresponding Author David A Proia, Synta Pharmaceuticals Corp, 125 Hartwell Avenue, Lexington, MA 02421
    Mol Cancer Ther 13:353-63. 2014
    ..Overall these data highlight the potential of ganetespib as a single-agent or combination treatment in BRAF(V600E)-driven melanoma, particularly as a strategy to overcome acquired resistance to selective BRAF inhibitors...
  3. pmc Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
    ..Taken together, these findings provide preclinical evidence for the use of this combination to treat patients with advanced NSCLC...
  4. doi request reprint Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
    Jim Sang
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Cancer Discov 3:430-43. 2013
    ..Taken together, these results highlight the therapeutic potential of ganetespib for ALK-driven NSCLC...
  5. doi request reprint Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
    ..Taken together, these data underscore the promise of ganetespib as a single-agent or combination treatment in KRAS-driven lung tumors...
  6. pmc Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
    ..Together these data suggest that further investigation of ganetespib as a new therapeutic treatment for prostate cancer patients is warranted...
  7. doi request reprint Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012
    ....
  8. doi request reprint Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
    Julie C Friedland
    Synta Pharmaceuticals Corp, 125 Hartwell Avenue, Lexington, MA, 02421, USA
    Invest New Drugs 32:14-24. 2014
    ..This preclinical activity profile suggests that ganetespib may offer considerable promise as a new therapeutic candidate for patients with advanced breast cancers. ..
  9. pmc Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
    Ronald K Blackman
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e29798. 2012
    ....
  10. doi request reprint Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise
    David A Proia
    Authors Affiliation Synta Pharmaceuticals Corp, Lexington, Massachusetts
    Cancer Res 74:1294-300. 2014
    ..Cancer Res; 74(5); 1294-300. ©2014 AACR. ..